AI Summary
Two different studies have found that oral muvalaplin and injectable olpasiran can reduce lipoprotein(a) levels, with no safety concerns.
Oral muvalaplin lowered lipoprotein(a) in a phase 1 study, and injectable olpasiran did so in an extension of a phase 2 study, both with no adverse safety signals, researchers report.
Medscape Medical News